Italian expert consensus for the management of actinic keratosis in immunocompetent patients

Journal of the European Academy of Dermatology and Venereology

Volumn 30, Issue 7, 2016, Pages 1077-1084

  Peris, K ^a   Calzavara Pinton, P G ^b   Neri, L ^c   Girolomoni, G ^d   Malara, G ^e   Parodi, A ^f   Piaserico, S ^g   Rossi, R ^h   Pellacani, G ⁱ  

^a CATHOLIC UNIVERSITY   (Italy)

^b UNIVERSITY OF BRESCIA   (Italy)

^c UNIVERSITY OF MILAN   (Italy)

^d UNIVERSITY OF VERONA   (Italy)

^e Institute of Dermatology   (Italy)

^f UNIVERSITY OF GENOA   (Italy)

^g UNIVERSITY OF PADOVA   (Italy)

^h UNIVERSITY OF FLORENCE   (Italy)

ⁱ UNIVERSITY OF MODENA AND REGGIO EMILIA   (Italy)

Author keywords

[No Author keywords available]

Indexed keywords

AMINOLEVULINIC ACID METHYL ESTER; DICLOFENAC; FLUOROURACIL; IMIQUIMOD; INGENOL MEBUTATE; SALICYLIC ACID;

ABLATION THERAPY; ACTINIC KERATOSIS; CANCER GROWTH; CANCER RISK; CASE MANAGEMENT; CLINICAL PRACTICE; CONSENSUS; COST EFFECTIVENESS ANALYSIS; CRYOSURGERY; CURETTAGE; ELECTRODESSICATION; EXCISION; HUMAN; ITALY; LASER SURGERY; PHOTODYNAMIC THERAPY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); REVIEW; SQUAMOUS CELL CARCINOMA;

EID: 84976487385     PISSN: 09269959     EISSN: 14683083     Source Type: Journal    
DOI: 10.1111/jdv.13648     Document Type: Review

References (66)

1. Naldi L, Chatenoud L, Piccitto R et al. Prevalence of actinic keratoses and associated factors in a representative sample of the Italian adult population: results from the Prevalence of Actinic Keratoses Italian Study, 2003-2004. Arch Dermatol 2006; 142: 722–726.
2. Harvey I, Frankel S, Marks R, Shalom D, Nolan-Farrell M. Non-melanoma skin cancer and solar keratoses. I. Methods and descriptive results of the South Wales Skin Cancer Study. Br J Cancer 1996; 74: 1302–1307.
3. Frost CA, Green AC, Williams GM. The prevalence and determinants of solar keratoses at a subtropical latitude (Queensland, Australia). Br J Dermatol 1998; 139: 1033–1039.
4. Frost C, Williams G, Green A. High incidence and regression rates of solar keratoses in a queensland community. J Invest Dermatol 2000; 115: 273–277.
5. Engel A, Johnson ML, Haynes SG. Health effects of sunlight exposure in the United States. Results from the first National Health and Nutrition Examination Survey, 1971-1974. Arch Dermatol 1988; 124: 72–79.
6. Werner RN, Sammain A, Erdmann R, Hartmann V, Stockfleth E, Nast A. The natural history of actinic keratosis: a systematic review. Br J Dermatol 2013; 169: 502–518.
7. Hollestein LM, de Vries E, Nijsten T. Trends of cutaneous squamous cell carcinoma in the Netherlands: increased incidence rates, but stable relative survival and mortality 1989-2008. Eur J Cancer 2012; 48: 2046–2053.
8. Stockfleth E, Kerl H; Guideline Subcommittee of the European Dermatology Forum. Guidelines for the management of actinic keratoses. Eur J Dermatol 2006; 16: 599–606.
9. de Berker D, McGregor JM, Hughes BR. Guidelines for the management of actinic keratosis. Br J Dermatol 2007; 156: 222–230.
10. Stockfleth E, Ferrandiz C, Grob JJ, Leigh I, Pehamberger H, Kerl H; European Skin Academy. Development of a treatment algorithm for actinic keratoses: a European Consensus. Eur J Dermatol 2008; 18: 651–659.
11. Rossi R, Calzavara-Pinton PG, Giannetti A et al. Italian guidelines and therapeutic algorithm for actinic keratoses. G Ital Dermatol Venereol 2009; 144: 713–723.
12. Werner RN, Stockfleth E, Connoly SM et al. Evidence and consensus based (S3) Guidelines for the Treatment of Actinic Keratosis. J Eur Acad Dermatol Venereol 2015; 29: 2069–2079.
13. Peserico A, Neri L, Calzavara Pinton P et al. Key Opinion Leader (KOL) Consensus for actinic keratosis management in Italy: the AKTUAL Workshop. G Ital Dermatol Venereol 2013; 148: 515–524.
14. Röwert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156(Suppl 3): S8–S12.
15. Anwar J, Wrone DA, Kimyai-Asadi A, Alam M. The development of actinic keratosis into invasive squamous cell carcinoma: evidence and evolving classification schemes. Clin Dermatol 2004; 22: 189–196.
16. Mittelbronn MA, Mullins DL, Ramos-Caro FA, Klowers FP. Frequency of pre-existing actinic keratosis in cutaneous squamous cell carcinoma. Int J Dermatol 1998; 37: 677–681.
17. Criscione VD, Weinstock MA, Naylor MF, Luque C, Eide MJ, Bingham SF. Actinic keratoses: natural history and risk of malignant transformation in the Veterans Affairs Topical Tretinoin Chemoprevention Trial. Cancer 2012; 115: 2523–2530.
18. Vatve M, Ortonne JP, Birch-Machin MA, Gupta G. Management of field change in actinic keratosis. Br J Dermatol 2007; 157(Suppl 2): 21–24.
19. Torezan LA, Festa-Neto C. Cutaneous field cancerization: clinical, histopathological and therapeutic aspects. An Bras Dermatol 2013; 88: 775–786.
20. Vanharanta S, Massagué J. Field cancerization: something new under the sun. Cell 2012; 149: 1179–1181.
21. Ziegler A, Jonason AS, Leffell DJ et al. Sunburn and p53 in the onset of skin cancer. Nature 1994; 372: 773–776.
22. Padilla RS, Sebastian S, Jiang Z, Nindl I, Larson R. Gene expression patterns of normal human skin, actinic keratosis, and squamous cell carcinoma: a spectrum of disease progression. Arch Dermatol 2010; 146: 288–293.
23. Berman B, Cockerell CJ. Pathobiology of actinic keratosis: ultraviolet-dependent keratinocyte proliferation. J Am Acad Dermatol 2013; 68(1 Suppl 1): S10–S19.
24. Ashton KJ, Weinstein SR, Maguire DJ, Griffiths LR. Chromosomal aberrations in squamous cell carcinoma and solar keratosis revealed by comparative genomic hybridization. Arch Dermatol 2003; 139: 876–882.
25. Riihilä PM, Nissinen LM, Ala-aho R et al. Complement factor H: a biomarker for progression of cutaneous squamous cell carcinoma. J Invest Dermatol 2014; 134: 498–506.
26. Riihilä P, Nissinen L, Farshchian M et al. Complement factor I promotes progression of cutaneous squamous cell carcinoma. J Invest Dermatol 2015; 135: 579–588.
27. Marks R. Who benefits from calling a solar keratosis a squamous cell carcinoma? Br J Dermatol 2006; 155: 23–26.
28. Peris K, Neri L, Calzavara Pinton PG et al. Physicians' opinions and clinical practice patterns for actinic keratosis management in Italy. G Ital Dermatol Venereol 2014; 149: 185–192.
29. Dodson JM, De Spain J, Hewett JE, Clark DP. Malignant potential of actinic keratoses and the controversy over treatment: a patientoriented perspective. Arch Dermatol 1991; 127: 1029–1031.
30. Whited JD, Horner RD, Hall RP, Simel DL. The influence of history on interobserver agreement for diagnosing actinic keratosis and malignant skin lesions. J Am Acad Dermatol 1995; 33: 603–607.
31. Huerta-Brogeras M, Olmos O, Borbujo J et al. Validation of dermoscopy as a real-time noninvasive diagnostic imaging technique for actinic keratosis. Arch Dermatol 2012; 148: 1159–1164.
32. Peris K, Micantonio T, Piccolo D, Concetta M. Dermoscopic features of actinic keratosis. J Dtsch Dermatol Ges 2007; 5: 970–975.
33. Malvehy J. A new vision of actinic keratosis beyond visible clinical lesions. J Eur Acad Dermatol Venereol 2015; 29(Suppl 1): 3–8.
34. Horn M, Gerger A, Ahlgrimm-Siess V et al. Discrimination of actinic keratoses from normal skin with reflectance mode confocal microscopy. Dermatol Surg 2008; 34: 620–625.
35. Farnetani F, Scope A, Braun RP et al. Skin cancer diagnosis with reflectance confocal microscopy: reproducibility of feature recognition and accuracy of diagnosis. JAMA Dermatol 2015; 151: 1075–1080.
36. Boone MA, Marneffe A, Suppa M et al. High-definition optical coherence tomography algorithm for the discrimination of actinic keratosis from normal skin and from squamous cell carcinoma. J Eur Acad Dermatol Venereol 2015; 29: 1606–1615.
37. Quaedvlieg PJ, Tirsi E, Thissen MR, Krekels GA. Actinic keratosis: how to differentiate the good from the bad ones? Eur J Dermatol 2006; 16: 335–339.
38. Olsen EA, Abernethy ML, Kulp-Shorten C et al. A double-blind, vehicle-controlled study evaluating masoprocol cream in the treatment of actinic keratoses on the head and neck. J Am Acad Dermatol 1991; 24: 738–743.
39. Rowert-Huber J, Patel MJ, Forschner T et al. Actinic keratosis is an early in situ squamous cell carcinoma: a proposal for reclassification. Br J Dermatol 2007; 156(Suppl 3): 8–12.
40. Fernández-Figueras MT, Carrato C, Sáenz X et al. Actinic keratosis with atypical basal cells (AK I) is the most common lesion associated with invasive squamous cell carcinoma of the skin. J Eur Acad Dermatol Venereol 2015; 29: 991–997.
41. Zalaudek I, Piana S, Moscarella E et al. Morphologic grading and treatment of facial actinic keratosis. Clin Dermatol 2014; 32: 80–87.
42. Ulrich C, Jurgensen JS, Degen A et al. Prevention of non-melanoma skin cancer in organ transplant patients by regular use of a sunscreen: a 24 months, prospective, case-control study. Br J Dermatol 2009; 161: 78–84.
43. van der Pols JC, Williams GM, Pandeya N, Logan V, Green AC. Prolonged prevention of squamous cell carcinoma of the skin by regular sunscreen use. Cancer Epidemiol Biomark Prev 2006; 15: 2546–2548.
44. Hirst NG, Gordon LG, Scuffham PA, Green AC. Lifetime cost-effectiveness of skin cancer prevention through promotion of daily sunscreen use. Value Health 2012; 15: 261–268.
45. Puviani M, Barcella A, Milani M. Efficacy of a photolyase-based device in the treatment of cancerization field in patients with actinic keratosis and non-melanoma skin cancer. G Ital Dermatol Venereol 2013; 148: 693–698.
46. Puviani M, Milani M. A Pilot, Prospective, Open-Label Study on the Effects of a Topical Photorepair and Photoprotection Film-Forming Medical Device in Patients with Actinic Keratoses Evaluated by Means of Skin Analysis Camera Antera 3D. J Clin Exp Dermatol Res 2015; 6: 2.
47. Puig S, Diaz A, Trullas C et al. Photolyase and UV filters fluid formulation in the treatment field cancerization of actinic keratosis: clinical, dermoscopy, confocal microscopy, and histopathologic improvements after 2 months of treatment. J Am Acad Dermatol 2014; 70: AB138.
48. Puig S, Puig-Butillé JA, Díaz MA, Trullas C, Malvehy J. Field cancerisation improvement with topical application of a film-forming medical device containing photolyase and UV filters in patients with actinic keratosis, a pilot study. J Clin Exp Dermatol Res 2014; 5: 220.
49. Yarosh D, Klein J, O'Connor A, Hawk J, Rafal E, Wolf P. Effect of topically applied T4 endonuclease V in liposomes on skin cancer in xeroderma pigmentosum: a randomised study. Xeroderma Pigmentosum Study Group. Lancet 2001; 357: 926–929.
50. Dotto GP. Multifocal epithelial tumors and field cancerization: stroma as a primary determinant. J Clin Invest 2014; 124: 1446–1453.
51. Schmitt AR, Bordeaux JS. Actinic neoplasia syndrome and an update on the epidemiology of basal cell carcinoma, squamous cell carcinoma, and actinic keratosis. Curr Dermatol Rep 2013; 2: 42–47.
52. Del RJ, Kircik L, Goldenberg G, Brian B. Comprehensive management of actinic keratoses: practical integration of available therapies with a review of a newer treatment approach. J Clin Aesthet Dermatol 2014; 7(9 Suppl S2-S12): S2–S12.
53. Hofbauer G, Anliker M, Boehncke WH et al. Swiss clinical practice guidelines on field cancerization of the skin. Swiss Med Wkly 2014; 144: w14026.
54. Berman B, Goldenberg G, Hanke CW et al. Efficacy and safety of ingenol mebutate 0.015% gel after cryosurgery of actinic keratosis: 12-month results. J Drugs Dermatol 2014; 13: 741–747.
55. Jorizzo JL, Markowitz O, Lebwohl MG et al. A randomized, double-blinded, placebo-controlled, multicenter, efficacy and safety study of 3.75% imiquimod cream following cryosurgery for the treatment of actinic keratoses. J Drugs Dermatol 2010; 9: 1101–1108.
56. Berlin JM, Rigel DS. Diclofenac sodium 3% gel in the treatment of actinic keratoses postcryosurgery. J Drugs Dermatol 2008; 7: 669–673.
57. Christensen H, Mørk C, Foss OA. Pre-treatment deep curettage can significantly reduce tumour thickness in thick basal cell carcinoma while maintaining a favourable cosmetic outcome when used in combination with topical photodynamic therapy. J Skin Cancer 2011;2011: 240340.
58. Gupta AK, Paquet M. Network meta-analysis of the outcome ‘participant complete clearance’ in non-immunosuppressed participants of eight interventions for actinic keratosis: a follow-up on a Cochrane review. Br J Dermatol 2013; 169: 250–259.
59. Vegter S, Tolley K. A network meta-analysis of the relative efficacy of treatments for actinic keratosis of the face or scalp in Europe. PLoS ONE 2014; 9: e96829.
60. Shergill B, Zokaie S, Carr AJ. Non-adherence to topical treatments for actinic keratosis. Patient Prefer Adherence 2013; 8: 35–41.
61. Erntoft S, Norlin J, Pollard C, Diepgen TL. Patient adherence and non-persistence behaviour in real life actinic keratosis (AK) topical treatment in the UK, Germany and France. Value Health 2014; 17: A287.
62. Gwadry-Sridhar FH, Manias E, Lal L et al. Impact of interventions on medication adherence and blood pressure control in patients with essential hypertension: a systematic review by the ISPOR medication adherence and persistence special interest group. Value Health 2013; 16: 863–871.
63. Stockfleth E, Peris K, Guillen C et al. A consensus approach to improving patient adherence and persistence with topical treatment for actinic keratosis. Int J Dermatol 2015; 54: 509–515.
64. Ricciardi W, Kheiraoui F, de Waure C et al. Valutazione dell'impatto clinico, economico etico ed organizzativo dell'introduzione di una nuova tecnologia sanitaria, Ingenolo Mebutato, nel trattamento della cheratosi attinica in Italia. QIJPH 2013; 2: 1–64.
65. Di Matteo S, Colombo GL, Pellacani G, Bruno GM. Cost-effectiveness analysis of ingenolo mebutato versus imiquimod in the treatment of actinic keratoses in the perspective of the Italian health system. Value Health 2014; 17, A608.
66. Zane C, Facchinetti E, Rossi MT, Specchia C, Calzavara-Pinton PG. A randomized clinical trial of photodynamic therapy with methyl aminolaevulinate vs. diclofenac 3% plus hyaluronic acid gel for the treatment of multiple actinic keratoses of the face and scalp. Br J Dermatol 2014; 170: 1143–1150.